Dr. Gene Griffin is an immunologist with 28+ years of drug development experience in pharmaceutical and biotechnology companies. He is currently a consultant in this industry. Formerly, Griffin was VP, Therapeutic Area Head for CureVac Inc. (a mRNA company) where he was responsible for the expansion of mRNA into rare diseases. Prior to that, he was Senior Director at Alexion Pharmaceuticals (a rare disease company) where he was instrumental in the clinical application and regulatory approval of Soliris® (C5 antibody) in Neuromyelitis optica and Myasthenia gravis. He is co-inventor on several of these patents. Additionally, he was key in Alexion's diversification into enzyme replacement therapies one of which was for a rare disease called Generalized Arterial Calcification of Infancy (GACI). He sponsored a relationship with Yale's Dr. Demetrios Braddock for the development ENPP1 enzyme for GACI which ultimately was the basis of formation of a company called Inozyme Pharma.

Griffin earned his Doctor of Veterinary Medicine degree at Tuskegee University and is a member of Phi Zeta Honor Society. He earned his Master and Bachelor of Science degrees from the University of Connecticut. He did his Postdoctoral research in Transplantation-Related Vascular Immunology at the Milton S. Hershey Medical Center, Pennsylvania State University.